Cargando…
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
OBJECTIVE: To quantify the healthcare expenditures associated with potential oral glucocorticoid (OGC)-related adverse events (AEs) in patients with giant cell arteritis (GCA). METHODS: Patients with GCA and ≥ 1 OGC prescription fill between 2009 and 2014 were identified from the MarketScan Commerci...
Autores principales: | Best, Jennie H, Kong, Amanda M, Smith, David M, Abbass, Ibrahim, Michalska, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934125/ https://www.ncbi.nlm.nih.gov/pubmed/31920351 http://dx.doi.org/10.2147/CEOR.S228400 |
Ejemplares similares
-
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
por: Best, Jennie H., et al.
Publicado: (2019) -
Estimating the Cost of Illness of Giant Cell Arteritis in the United States
por: Babigumira, Joseph B., et al.
Publicado: (2017) -
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019) -
The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis
por: Jakobsson, Karin, et al.
Publicado: (2016) -
Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis
por: Karabayas, Maira, et al.
Publicado: (2020)